CompletedNCT02466685
JNJ-18038683 for Cognitive and Depressive Symptoms in Bipolarity
About this title
Read the official source — NCT02466685Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- ChicagoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Herbert Meltzer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02466685
- Official title
Show the full official title
Testing the Ability of JNJ(Janssen and Janssen)18038683, a Selective Serotonin (5-HT)7 Antagonist, to Improve Cognition and Reduce Residual Depressive Symptoms in Stable Bipolar Patients (18038683BCD2001)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chicago
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Herbert Meltzer.
Did this study involve medication?
Yes. The study involved medication, including JNJ-18038683 and Placebo.
Who was this study for?
Listed age limits: 18 years to 60 years.
